The understanding of the use of donor lymphocyte infusions (DLI) for graft-versus- @entity1778 (GVL) in the treatment of @entity1860 ( @entity1860 ) post haemopoietic stem cell transplant (HSCT) has advanced during the last years. In relapsed @entity1778 post-stem cell transplant, DLI can achieve durable remissions in 60-73% @entity1 . Technical improvements in molecular methods of detection of the @entity1861 transcripts permit the prediction of relapse with increased sensitivity and reproducibility. Use of DLI early at relapse is important since responses to DLI are less likely in the face of bulky or @entity9638 . Exogenous @entity1199 may enhance the response to DLI but total cell dose is also relevant to the efficacy of DLI with the effective cell dose (ECD) required being lower in HLA matched unrelated DLI donors compared to siblings. Donor T-lymphocytes target minor histocompatibility (H) antigens and the relative tissue distribution of these may influence the @entity137 of DLI, which includes @entity2132 ( @entity2132 ). Modified methods of delivery such as selective deletion of @entity405 + cells or escalating cell dosage regimens have reduced the incidence of serious morbidity due to @entity2132 without compromising the GVL effect mediated by DLI. These approaches have not removed the risk of @entity2132 entirely and conditional suicide protocols utilising the HSV-tk or fas receptor derived genes are being developed in the clinic. Since significant morbidity and mortality is attributable to the conditioning regimen used prior to HSCT, awareness of the potency of DLI has driven the development of reduced intensity conditioning (RIC) regimens. The purpose of RIC is to enhance tolerisation of the host to the graft while permitting the establishment of donor haemopoiesis. DLI may then be used subsequently to enhance the GVL effect.

Donor lymphocyte infusions for @entity1 who relapse after allogeneic stem cell transplantation for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1861 :: ('25', 'Gene') :: ['BCR-ABL'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity9638 :: ('MESH:D001752', 'Disease') :: ['blast-phase disease'] @entity405 :: ('925', 'Gene') :: ['CD8'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukaemia'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['GVHD', 'graft-versus-host-disease'] @entity1199 :: ('3558', 'Gene') :: ['interleukin-2'] @entity1860 :: ('MESH:D015464', 'Disease') :: ['CML', 'chronic myeloid leukaemia']
@entity1860 :: (MESH:D015464,Disease) :: ['chronic myeloid leukaemia']
